-
Product Insights
New![]()
Net Present Value Model: Inhibikase Therapeutics Inc’s Risvodetinib
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SAP-001 in Hyperuricemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SAP-001 in Hyperuricemia Drug Details: SAP-001 is under development for the treatment of gout and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Risvodetinib in Constipation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib in Constipation Drug Details: Risvodetinib (Ikt-148009) is under development for the treatment of Parkinson’s disease...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Risvodetinib in Dysphagia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib in Dysphagia Drug Details: Risvodetinib (Ikt-148009) is under development for the treatment of Parkinson’s disease...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tunlametinib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tunlametinib in Solid Tumor Drug Details: Tunlametinib (HL-085) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PBCAR-20A in Refractory Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PBCAR-20A in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:PBCAR-20A is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imatinib Mesylate in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib Mesylate in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drug Details: Imatinib mesylate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Afamitresgene Autoleucel in Squamous Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Afamitresgene Autoleucel in Squamous Non-Small Cell Lung Cancer Drug Details: ADPA-2M4 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anzurstobart in Head And Neck Cancer Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anzurstobart in Head And Neck Cancer Squamous Cell Carcinoma Drug Details: CC-95251 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Skin Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Skin Cancer Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.